United States Biotechnology & Medical Research

Aimmune Therapeutics Inc (AIMT)

Track

Ticker: AIMT Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.6
ENRIGHT PATRICK G Non-Executive Director
Transaction date
Purchase
Price
448.03
Quantity 77,492 -25.1%
Value US$1,256,199
3.6
ENRIGHT PATRICK G Non-Executive Director
Transaction date
Purchase
Price
11.50
Quantity 8,787 +19.3%
Value US$101,050
3.6
ENRIGHT PATRICK G Non-Executive Director
Transaction date
Purchase
Price
11.40
Quantity 100,000 +1.7%
Value US$1,139,650
Oxtoby Andrew Chief Commercial Officer Officer
Transaction date
Purchase
Price
14.76
Quantity 3,000 +13.6%
Value US$44,266
3.2
BJERKHOLT ERIC Chief Financial Officer Officer
Transaction date
Purchase
Price
15.10
Quantity 1,000 +2.4%
Value US$15,100
3.2
BJERKHOLT ERIC Chief Financial Officer Officer
Transaction date
Purchase
Price
18.97
Quantity 1,000 +2.4%
Value US$18,970
Sheehy Douglas T. See Remarks
Transaction date
Planned sale
Price
37.00
Quantity 400 -0.9%
Value US$14,800
ADELMAN DANIEL C MD Chief Medical Officer
Transaction date
Planned sale
Price
35.00
Quantity 20,000 -48.5%
Value US$700,038
Sheehy Douglas T. See Remarks Officer
Transaction date
Planned sale
Price
33.03
Quantity 10,000 -18.0%
Value US$330,322
ADELMAN DANIEL C MD Chief Medical Officer Officer
Transaction date
Planned sale
Price
30.04
Quantity 20,000 -48.5%
Value US$600,716
3.2
BJERKHOLT ERIC Chief Financial Officer
Transaction date
Purchase
Price
22.57
Quantity 1,550 +4.8%
Value US$34,977
Barrowcliffe Susan E. General Manager, Europe Officer
Transaction date
Sale
Price
30.04
Quantity 40,000 -81.0%
Value US$1,201,600
Dallas Jayson Donald Alexander President and CEO Executive Director
Transaction date
Purchase
Price
27.56
Quantity 50 +0.1%
Value US$1,378
Dallas Jayson Donald Alexander President and CEO Executive Director
Transaction date
Purchase
Price
27.56
Quantity 3,600 +6.0%
Value US$99,209
3.2
BJERKHOLT ERIC Chief Financial Officer
Transaction date
Planned purchase
Price
30.41
Quantity 1,600 +8.9%
Value US$48,663
DILLY STEPHEN GEORGE President and CEO Executive Director
Transaction date
Planned sale
Price
30.83
Quantity 29,457 -8.5%
Value US$908,301
DILLY STEPHEN GEORGE President and CEO Executive Director
Transaction date
Planned sale
Price
30.70
Quantity 42,106 -11.8%
Value US$1,292,511
DILLY STEPHEN GEORGE President and CEO Executive Director
Transaction date
Planned sale
Price
31.58
Quantity 500 -0.2%
Value US$15,790
DILLY STEPHEN GEORGE President and CEO Executive Director
Transaction date
Planned sale
Price
30.95
Quantity 32,098 -9.2%
Value US$993,321
DILLY STEPHEN GEORGE President and CEO Executive Director
Transaction date
Planned sale
Price
31.20
Quantity 30,465 -8.8%
Value US$950,371
DILLY STEPHEN GEORGE See Remarks Executive Director
Transaction date
Planned sale
Price
31.83
Quantity 38,825 -11.0%
Value US$1,235,835
DILLY STEPHEN GEORGE See Remarks Executive Director
Transaction date
Planned sale
Price
32.74
Quantity 2,612 -0.8%
Value US$85,519
DILLY STEPHEN GEORGE See Remarks Executive Director
Transaction date
Planned sale
Price
31.84
Quantity 62,740 -16.5%
Value US$1,997,836
DILLY STEPHEN GEORGE See Remarks Executive Director
Transaction date
Planned sale
Price
33.19
Quantity 2,498 -0.8%
Value US$82,899
DILLY STEPHEN GEORGE See Remarks Executive Director
Transaction date
Planned sale
Price
32.59
Quantity 58,699 -15.6%
Value US$1,913,094
Sheehy Douglas T. See Remarks Officer
Transaction date
Planned sale
Price
33.00
Quantity 1,648 -4.7%
Value US$54,384
Sheehy Douglas T. See Remarks Officer
Transaction date
Planned sale
Price
33.00
Quantity 1,648 -4.7%
Value US$54,384
Sheehy Douglas T. See Remarks
Transaction date
Planned sale
Price
36.60
Quantity 700 -2.1%
Value US$25,618
Sheehy Douglas T. See Remarks
Transaction date
Planned sale
Price
35.52
Quantity 948 -2.8%
Value US$33,674
Sheehy Douglas T. See Remarks
Transaction date
Planned sale
Price
37.00
Quantity 1,875 -5.5%
Value US$69,375
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
33.10
Quantity 1,807 -93.3%
Value US$59,812
BJERKHOLT ERIC Chief Financial Officer Officer
Transaction date
Purchase
Price
32.00
Quantity 3,125 +62.5%
Value US$100,000
FALBERG KATHRYN E Non-Executive Director
Transaction date
Purchase
Price
32.00
Quantity 30,000 +31.6%
Value US$960,000
Iwicki Mark T Non-Executive Director
Transaction date
Purchase
Price
32.00
Quantity 9,375 +46.9%
Value US$300,000
ENRIGHT PATRICK G Non-Executive Director Large shareholder
Transaction date
Purchase
Price
32.00
Quantity 15,593 +214.3%
Value US$498,976
Tammenoms Bakker Juliet Large shareholder
Transaction date
Purchase
Price
32.00
Quantity 9,375 +128.8%
Value US$300,000
Sheehy Douglas T. See Remarks Officer
Transaction date
Planned sale
Price
35.87
Quantity 1,648 -100.0%
Value US$59,114
Rozenman Mary M. See Remarks Officer
Transaction date
Planned sale
Price
35.58
Quantity 4,292 -97.1%
Value US$152,703
Rozenman Mary M. See Remarks Officer
Transaction date
Planned sale
Price
34.95
Quantity 2,300 -34.2%
Value US$80,385
Sheehy Douglas T. See Remarks Officer
Transaction date
Planned sale
Price
38.15
Quantity 1,875 -100.0%
Value US$71,531
ADELMAN DANIEL C MD Chief Medical Officer Officer
Transaction date
Planned sale
Price
40.00
Quantity 9,933 -100.0%
Value US$397,320
ADELMAN DANIEL C MD Chief Medical Officer Officer
Transaction date
Planned sale
Price
40.00
Quantity 26,784 -100.0%
Value US$1,071,360
Sheehy Douglas T. See Remarks Officer
Transaction date
Planned sale
Price
37.33
Quantity 1,648 -100.0%
Value US$61,520
Barrowcliffe Susan E. General Manager, Europe Officer
Transaction date
Planned sale
Price
37.75
Quantity 600 -100.0%
Value US$22,652
Barrowcliffe Susan E. General Manager, Europe Officer
Transaction date
Planned sale
Price
37.12
Quantity 24,400 -97.6%
Value US$905,716
Barrowcliffe Susan E. General Manager, Europe Officer
Transaction date
Planned sale
Price
37.86
Quantity 300 -1.2%
Value US$11,359
Barrowcliffe Susan E. General Manager, Europe Officer
Transaction date
Planned sale
Price
37.13
Quantity 24,700 -49.4%
Value US$917,022
Barrowcliffe Susan E. General Manager, Europe Officer
Transaction date
Planned sale
Price
37.78
Quantity 599 -1.2%
Value US$22,629
Barrowcliffe Susan E. General Manager, Europe Officer
Transaction date
Planned sale
Price
37.12
Quantity 24,401 -32.5%
Value US$905,811
Rozenman Mary M. See Remarks Officer
Transaction date
Planned sale
Price
37.08
Quantity 1,601 -92.5%
Value US$59,367
Rozenman Mary M. See Remarks Officer
Transaction date
Planned sale
Price
37.12
Quantity 4,990 -74.3%
Value US$185,223
ADELMAN DANIEL C MD Chief Medical Officer
Transaction date
Planned sale
Price
40.00
Quantity 3,283 -100.0%
Value US$131,320
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
39.15
Quantity 3,600 -96.5%
Value US$140,949
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
38.73
Quantity 6,400 -63.2%
Value US$247,848
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
39.28
Quantity 1,200 -10.6%
Value US$47,134
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
38.83
Quantity 8,800 -43.7%
Value US$341,663
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
39.26
Quantity 700 -3.4%
Value US$27,479
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
38.80
Quantity 4,310 -17.1%
Value US$167,239
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
39.23
Quantity 1,500 -5.6%
Value US$58,847
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
38.82
Quantity 11,000 -29.2%
Value US$427,043
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
39.25
Quantity 1,500 -3.8%
Value US$58,875
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
38.83
Quantity 11,000 -21.9%
Value US$427,115
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
39.23
Quantity 1,800 -3.5%
Value US$70,605
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
38.82
Quantity 10,700 -17.1%
Value US$415,322
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
39.25
Quantity 1,500 -2.3%
Value US$58,878
Rozenman Mary M. See Remarks
Transaction date
Planned sale
Price
38.83
Quantity 11,000 -14.6%
Value US$427,089
Sheehy Douglas T. See Remarks
Transaction date
Planned sale
Price
39.44
Quantity 1,875 -100.0%
Value US$73,950
Sheehy Douglas T. See Remarks
Transaction date
Planned sale
Price
38.66
Quantity 1,906 -100.0%
Value US$73,686
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2020-10-15 2020-10-13 B Purchase
2.9
Societe des Produits Nestle S.A.
Large shareholder
73,388 +32.6%
354.97
US$2,135,657 		73,388 +32.6% 354.97 US$2,135,657
2020-10-15 2020-10-13 B Purchase
2.9
Societe des Produits Nestle S.A.
Large shareholder
32,490 +20.8%
451.38
US$3,337,609 		32,490 +20.8% 451.38 US$3,337,609
2020-03-19 2020-03-18 B Purchase
3.6
ENRIGHT PATRICK G
Non-Executive Director
77,492 -25.1%
448.03
US$1,256,199 		77,492 -25.1% 448.03 US$1,256,199
2020-03-19 2020-03-17 B Purchase
3.6
ENRIGHT PATRICK G
Non-Executive Director
8,787 +19.3%
11.50
US$101,050 		8,787 +19.3% 11.50 US$101,050
2020-03-19 2020-03-17 B Purchase
3.6
ENRIGHT PATRICK G
Non-Executive Director
100,000 +1.7%
11.40
US$1,139,650 		100,000 +1.7% 11.40 US$1,139,650
2020-03-17 2020-03-13 B Purchase
Oxtoby Andrew

Chief Commercial Officer

Officer
3,000 +13.6%
14.76
US$44,266 		3,000 +13.6% 14.76 US$44,266
2020-03-12 2020-03-12 B Purchase
3.2
BJERKHOLT ERIC

Chief Financial Officer

Officer
1,000 +2.4%
15.10
US$15,100 		1,000 +2.4% 15.10 US$15,100
2020-03-10 2020-03-10 B Purchase
Dallas Jayson Donald Alexander

President and CEO

Executive Director
2,665 +2.2%
18.74
US$49,934 		2,665 +2.2% 18.74 US$49,934
2020-03-10 2020-03-09 B Purchase
3.2
BJERKHOLT ERIC

Chief Financial Officer

Officer
1,000 +2.4%
18.97
US$18,970 		1,000 +2.4% 18.97 US$18,970
2020-04-24 2020-02-07 B Purchase
2.9
Societe des Produits Nestle S.A.
Large shareholder
525,634 +inf%
319.68
US$168,032,049 		525,634 +inf% 319.68 US$168,032,049
2020-04-24 2020-02-07 B Purchase
2.9
Societe des Produits Nestle S.A.
Large shareholder
1,000,000 +8.5%
31.97
US$31,970,000 		1,000,000 +8.5% 31.97 US$31,970,000
2020-01-21 2020-01-16 PlS Planned sale
Sheehy Douglas T.

See Remarks
400 -0.9%
37.00
US$14,800 		400 -0.9% 37.00 US$14,800
2020-01-03 2020-01-02 PlS Planned sale
ADELMAN DANIEL C MD

Chief Medical Officer
20,000 -48.5%
35.00
US$700,038 		20,000 -48.5% 35.00 US$700,038
2019-12-30 2019-12-26 PlS Planned sale Sheehy Douglas T.

See Remarks

Officer
10,000 -18.0%
33.03
US$330,322 		10,000 -18.0% 33.03 US$330,322
2019-12-11 2019-12-09 PlS Planned sale ADELMAN DANIEL C MD

Chief Medical Officer

Officer
20,000 -48.5%
30.04
US$600,716 		20,000 -48.5% 30.04 US$600,716
2019-09-20 2019-09-18 B Purchase
3.2
BJERKHOLT ERIC

Chief Financial Officer
1,550 +4.8%
22.57
US$34,977 		1,550 +4.8% 22.57 US$34,977
2020-04-24 2018-11-28 B Purchase
Nestle Health Science US Holdings, Inc.
Large shareholder
3,237,529 +38.1%
30.27
US$98,000,003 		3,237,529 +38.1% 30.27 US$98,000,003
2018-11-21 2018-11-19 S Sale Barrowcliffe Susan E.

General Manager, Europe

Officer
40,000 -81.0%
30.04
US$1,201,600 		40,000 -81.0% 30.04 US$1,201,600
2018-11-19 2018-11-19 B Purchase Dallas Jayson Donald Alexander

President and CEO

Executive Director
50 +0.1%
27.56
US$1,378 		50 +0.1% 27.56 US$1,378
2018-11-19 2018-11-19 B Purchase Dallas Jayson Donald Alexander

President and CEO

Executive Director
3,600 +6.0%
27.56
US$99,209 		3,600 +6.0% 27.56 US$99,209
2018-06-14 2018-06-13 PP Planned purchase
3.2
BJERKHOLT ERIC

Chief Financial Officer
1,600 +8.9%
30.41
US$48,663 		1,600 +8.9% 30.41 US$48,663
2018-06-13 2018-06-11 PlS Planned sale DILLY STEPHEN GEORGE

President and CEO

Executive Director
29,457 -8.5%
30.83
US$908,301 		29,457 -8.5% 30.83 US$908,301
2018-06-08 2018-06-08 PlS Planned sale DILLY STEPHEN GEORGE

President and CEO

Executive Director
42,106 -11.8%
30.70
US$1,292,511 		42,106 -11.8% 30.70 US$1,292,511
2018-06-08 2018-06-07 PlS Planned sale DILLY STEPHEN GEORGE

President and CEO

Executive Director
500 -0.2%
31.58
US$15,790 		500 -0.2% 31.58 US$15,790
2018-06-08 2018-06-07 PlS Planned sale DILLY STEPHEN GEORGE

President and CEO

Executive Director
32,098 -9.2%
30.95
US$993,321 		32,098 -9.2% 30.95 US$993,321
2018-06-08 2018-06-06 PlS Planned sale DILLY STEPHEN GEORGE

President and CEO

Executive Director
30,465 -8.8%
31.20
US$950,371 		30,465 -8.8% 31.20 US$950,371
2018-06-05 2018-06-05 PlS Planned sale DILLY STEPHEN GEORGE

See Remarks

Executive Director
38,825 -11.0%
31.83
US$1,235,835 		38,825 -11.0% 31.83 US$1,235,835
2018-06-05 2018-06-04 PlS Planned sale DILLY STEPHEN GEORGE

See Remarks

Executive Director
2,612 -0.8%
32.74
US$85,519 		2,612 -0.8% 32.74 US$85,519
2018-06-05 2018-06-04 PlS Planned sale DILLY STEPHEN GEORGE

See Remarks

Executive Director
62,740 -16.5%
31.84
US$1,997,836 		62,740 -16.5% 31.84 US$1,997,836
2018-06-05 2018-06-01 PlS Planned sale DILLY STEPHEN GEORGE

See Remarks

Executive Director
2,498 -0.8%
33.19
US$82,899 		2,498 -0.8% 33.19 US$82,899
2018-06-05 2018-06-01 PlS Planned sale DILLY STEPHEN GEORGE

See Remarks

Executive Director
58,699 -15.6%
32.59
US$1,913,094 		58,699 -15.6% 32.59 US$1,913,094
2018-05-24 2018-05-22 PlS Planned sale Sheehy Douglas T.

See Remarks

Officer
1,648 -4.7%
33.00
US$54,384 		1,648 -4.7% 33.00 US$54,384
2018-05-24 2018-05-22 PlS Planned sale Sheehy Douglas T.

See Remarks

Officer
1,648 -4.7%
33.00
US$54,384 		1,648 -4.7% 33.00 US$54,384
2018-03-06 2018-03-05 PlS Planned sale Sheehy Douglas T.

See Remarks
700 -2.1%
36.60
US$25,618 		700 -2.1% 36.60 US$25,618
2018-03-06 2018-03-05 PlS Planned sale Sheehy Douglas T.

See Remarks
948 -2.8%
35.52
US$33,674 		948 -2.8% 35.52 US$33,674
2018-03-06 2018-03-05 PlS Planned sale Sheehy Douglas T.

See Remarks
1,875 -5.5%
37.00
US$69,375 		1,875 -5.5% 37.00 US$69,375
2018-03-05 2018-03-01 PlS Planned sale Rozenman Mary M.

See Remarks
1,807 -93.3%
33.10
US$59,812 		1,807 -93.3% 33.10 US$59,812
2020-04-24 2018-02-26 B Purchase
Nestle Health Science US Holdings, Inc.
Large shareholder
937,500 +12.4%
32.00
US$30,000,000 		937,500 +12.4% 32.00 US$30,000,000
2018-02-26 2018-02-26 B Purchase BJERKHOLT ERIC

Chief Financial Officer

Officer
3,125 +62.5%
32.00
US$100,000 		3,125 +62.5% 32.00 US$100,000
2018-02-26 2018-02-26 B Purchase FALBERG KATHRYN E Non-Executive Director
30,000 +31.6%
32.00
US$960,000 		30,000 +31.6% 32.00 US$960,000
2018-02-26 2018-02-26 B Purchase Iwicki Mark T Non-Executive Director
9,375 +46.9%
32.00
US$300,000 		9,375 +46.9% 32.00 US$300,000
2018-02-26 2018-02-22 B Purchase ENRIGHT PATRICK G Non-Executive Director Large shareholder
15,593 +214.3%
32.00
US$498,976 		15,593 +214.3% 32.00 US$498,976
2018-02-26 2018-02-22 B Purchase Tammenoms Bakker Juliet Large shareholder
9,375 +128.8%
32.00
US$300,000 		9,375 +128.8% 32.00 US$300,000
2018-02-07 2018-02-05 PlS Planned sale Sheehy Douglas T.

See Remarks

Officer
1,648 -100.0%
35.87
US$59,114 		1,648 -100.0% 35.87 US$59,114
2018-02-05 2018-02-01 PlS Planned sale Rozenman Mary M.

See Remarks

Officer
4,292 -97.1%
35.58
US$152,703 		4,292 -97.1% 35.58 US$152,703
2018-02-05 2018-02-01 PlS Planned sale Rozenman Mary M.

See Remarks

Officer
2,300 -34.2%
34.95
US$80,385 		2,300 -34.2% 34.95 US$80,385
2018-01-26 2018-01-24 PlS Planned sale Sheehy Douglas T.

See Remarks

Officer
1,875 -100.0%
38.15
US$71,531 		1,875 -100.0% 38.15 US$71,531
2018-01-16 2018-01-16 PlS Planned sale ADELMAN DANIEL C MD

Chief Medical Officer

Officer
9,933 -100.0%
40.00
US$397,320 		9,933 -100.0% 40.00 US$397,320
2018-01-16 2018-01-12 PlS Planned sale ADELMAN DANIEL C MD

Chief Medical Officer

Officer
26,784 -100.0%
40.00
US$1,071,360 		26,784 -100.0% 40.00 US$1,071,360
2018-01-08 2018-01-04 PlS Planned sale Sheehy Douglas T.

See Remarks

Officer
1,648 -100.0%
37.33
US$61,520 		1,648 -100.0% 37.33 US$61,520
2018-01-04 2018-01-02 PlS Planned sale Barrowcliffe Susan E.

General Manager, Europe

Officer
600 -100.0%
37.75
US$22,652 		600 -100.0% 37.75 US$22,652
2018-01-04 2018-01-02 PlS Planned sale Barrowcliffe Susan E.

General Manager, Europe

Officer
24,400 -97.6%
37.12
US$905,716 		24,400 -97.6% 37.12 US$905,716
2018-01-04 2018-01-02 PlS Planned sale Barrowcliffe Susan E.

General Manager, Europe

Officer
300 -1.2%
37.86
US$11,359 		300 -1.2% 37.86 US$11,359
2018-01-04 2018-01-02 PlS Planned sale Barrowcliffe Susan E.

General Manager, Europe

Officer
24,700 -49.4%
37.13
US$917,022 		24,700 -49.4% 37.13 US$917,022
2018-01-04 2018-01-02 PlS Planned sale Barrowcliffe Susan E.

General Manager, Europe

Officer
599 -1.2%
37.78
US$22,629 		599 -1.2% 37.78 US$22,629
2018-01-04 2018-01-02 PlS Planned sale Barrowcliffe Susan E.

General Manager, Europe

Officer
24,401 -32.5%
37.12
US$905,811 		24,401 -32.5% 37.12 US$905,811
2018-01-04 2018-01-02 PlS Planned sale Rozenman Mary M.

See Remarks

Officer
1,601 -92.5%
37.08
US$59,367 		1,601 -92.5% 37.08 US$59,367
2018-01-04 2018-01-02 PlS Planned sale Rozenman Mary M.

See Remarks

Officer
4,990 -74.3%
37.12
US$185,223 		4,990 -74.3% 37.12 US$185,223
2017-12-29 2017-12-27 PlS Planned sale ADELMAN DANIEL C MD

Chief Medical Officer
3,283 -100.0%
40.00
US$131,320 		3,283 -100.0% 40.00 US$131,320
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
3,600 -96.5%
39.15
US$140,949 		3,600 -96.5% 39.15 US$140,949
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
6,400 -63.2%
38.73
US$247,848 		6,400 -63.2% 38.73 US$247,848
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
1,200 -10.6%
39.28
US$47,134 		1,200 -10.6% 39.28 US$47,134
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
8,800 -43.7%
38.83
US$341,663 		8,800 -43.7% 38.83 US$341,663
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
700 -3.4%
39.26
US$27,479 		700 -3.4% 39.26 US$27,479
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
4,310 -17.1%
38.80
US$167,239 		4,310 -17.1% 38.80 US$167,239
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
1,500 -5.6%
39.23
US$58,847 		1,500 -5.6% 39.23 US$58,847
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
11,000 -29.2%
38.82
US$427,043 		11,000 -29.2% 38.82 US$427,043
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
1,500 -3.8%
39.25
US$58,875 		1,500 -3.8% 39.25 US$58,875
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
11,000 -21.9%
38.83
US$427,115 		11,000 -21.9% 38.83 US$427,115
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
1,800 -3.5%
39.23
US$70,605 		1,800 -3.5% 39.23 US$70,605
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
10,700 -17.1%
38.82
US$415,322 		10,700 -17.1% 38.82 US$415,322
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
1,500 -2.3%
39.25
US$58,878 		1,500 -2.3% 39.25 US$58,878
2017-12-28 2017-12-26 PlS Planned sale Rozenman Mary M.

See Remarks
11,000 -14.6%
38.83
US$427,089 		11,000 -14.6% 38.83 US$427,089
2017-12-28 2017-12-26 PlS Planned sale Sheehy Douglas T.

See Remarks
1,875 -100.0%
39.44
US$73,950 		1,875 -100.0% 39.44 US$73,950
2017-12-06 2017-12-04 PlS Planned sale Sheehy Douglas T.

See Remarks
1,906 -100.0%
38.66
US$73,686 		1,906 -100.0% 38.66 US$73,686
Explore more

More insider trading research around Aimmune Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America